Breathing new life into a brighter tomorrow
ONSPIRA THERAPEUTICS is focused on the development of life-changing medicines to bring hope to patients suffering from rare pulmonary diseases. Our lead program is a novel, inhaled interleukin-1 alpha and beta (IL-1 𝛼 & β) receptor antagonist protein being advanced for the treatment of bronchiolitis obliterans syndrome (BOS) in post-lung transplant patients. BOS is a significant, often fatal condition affecting thousands of patients around the world. Additional development programs will address BOS following hematopoietic stem cell transplantation (HSCT), BOS caused by chemical exposure, interstitial pulmonary fibrosis and cystic fibrosis.